Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc., a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, and consumer health products, is headquartered in the United States. Founded in 2007, Catalent has rapidly expanded its operations across North America, Europe, and Asia, establishing a strong presence in the pharmaceutical and biotechnology industries. The company is renowned for its innovative core services, including drug formulation, clinical supply services, and commercial manufacturing, which are designed to enhance product efficacy and patient compliance. Catalent's commitment to quality and efficiency has positioned it as a trusted partner for many of the world's top pharmaceutical companies. With a focus on continuous improvement and cutting-edge technology, Catalent Pharma Solutions continues to achieve significant milestones, solidifying its status as a leader in the life sciences sector.
DitchCarbon Score
How does Catalent Pharma Solutions, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Catalent Pharma Solutions, Inc.'s score of 35 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Catalent Pharma Solutions, Inc.'s reported carbon emissions
Catalent Pharma Solutions, Inc., headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets for the near term. Catalent is committed to reducing its absolute Scope 1 and Scope 2 GHG emissions by 42% by FY2030, using FY2022 as the baseline year. Additionally, the company aims to achieve a 25% reduction in absolute Scope 3 GHG emissions, which include emissions from fuel- and energy-related activities and employee commuting, within the same timeframe. Furthermore, Catalent plans to ensure that 70% of its suppliers, measured by emissions, will have science-based targets by FY2028, covering areas such as purchased goods and services, capital goods, and upstream transportation and distribution. These commitments align with industry standards for climate action, reflecting Catalent's dedication to sustainability and its role in the pharmaceutical and biotechnology sector. The targets are consistent with the reductions necessary to limit global warming to 1.5°C, demonstrating the company's proactive approach to addressing climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Catalent Pharma Solutions, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
